InvenireX builds a DNA nanotechnology platform to detect disease at early biological stages.
Newcastle-based InvenireX has developed a DNA nanotechnology platform designed to detect early-stage disease markers. The technology utilises programmable structures and artificial intelligence to identify molecular targets with high sensitivity.
Daniel Todd
Founder
Dan Todd
CEO and founder
The funding round was led by DSW Ventures with participation from XTX Ventures, Cambridge Technology Capital, angel investors, and Innovate UK.
DSW Ventures and XTX Ventures backed the pre-seed round, which will fund prototype optimisation and technical validation.
